Ad
related to: rifaximin- Learn More
Learn About Xifaxan® (rifaximin)
As A Treatment Option.
- Healthcare Professionals
Obtain Product Information
Relevant To Your Patients.
- Patient Stories
Hear From Real Patients Experience
With Xifaxan® (rifaximin).
- Resources & Support
Browse Our Resources & Information.
View The Doctor Discussion Guide.
- Learn More
Search results
Results From The WOW.Com Content Network
Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of gastrointestinal diseases like ...
A common antibiotic used to treat liver disease could give rise to an “almost untreatable” superbug, scientists warned in a new study.. The antibiotic, rifaximin, has enabled the global ...
Is rifaximin (Xifaxan) covered under the Medicare formulary? Each Part D plan and Part C plan with drug coverage has its own formulary, or drug list. The drug list is divided into tiers. A drug ...
Medicare Part D prescription drug coverage helps cover the cost of Xifaxan (rifaximin). Doctors may recommend Xifaxan to treat irritable bowel syndrome with diarrhea (IBS-D) or to help prevent ...
The rifamycin group includes the classic rifamycin drugs as well as the rifamycin derivatives rifampicin (or rifampin), rifabutin, rifapentine, rifalazil and rifaximin. Rifamycin, sold under the trade name Aemcolo, is approved in the United States for treatment of travelers' diarrhea in some circumstances. [1] [2] [3]
When rifaximin is added to lactulose, the combination of the two may be more effective than each component separately. [4] Rifaximin is more expensive than lactulose, but the cost may be offset by fewer hospital admissions for encephalopathy. [19] The antibiotics neomycin and metronidazole are other antibiotics used to treat hepatic ...
Small intestinal bacterial overgrowth (SIBO), also termed bacterial overgrowth, or small bowel bacterial overgrowth syndrome (SBBOS), is a disorder of excessive bacterial growth in the small intestine.
Tetracyclines have been the mainstay of treatment for blind loop syndrome, but recent studies have concluded rifaximin to be very effective in the treatment of blind loop syndrome. However, a study by Di Stefano et al. concluded metronidazole to be more effective than rifaximin in the treatment of blind loop syndrome. [citation needed]
Ad
related to: rifaximin